CDK5 and cancer: For each cancer cell line, 6 groups of 10 mice were treated for 4 weeks as follows: 1) DOPC nanoliposomes, 2) control siRNA-DOPC, 3) CDK5 siRNA-DOPC, 4) paclitaxel, or 5) a combination of control siRNA-DOPC plus paclitaxel, or 6) a combination of CDK5 siRNA-DOPC plus paclitaxel.